[mRNA expression of IGF-IIand HGF in relation to microvascular density, tumor progression and prognosis of gastric carcinoma].
OBJECTIVE
To investigate whether correlation exists between mRNA expression of IGF-II and hepatocyte growth factor (HGF) and tumor progression and prognosis in gastric cancer.


METHODS
In situ hybridization technique was used to examine mRNA expression of IGF-II and HGF, and immunohistochemical technique was used to examine protein expression of CD34 in 105 specimens of gastric carcinoma.


RESULTS
In situ hybridization revealed that the positive rates of IGF-II mRNA and HGFmRNA were 49.5% and 57.1%, respectively. In stage T3-T4 cases, positive mRNA expression rates of IGF-II and HGF, the frequencies of vessel invasion, lymph node metastasis and distant metastasis were significantly higher than those in stage T1-T2 cases. The mean microvascular density (MVD) in stage T3-T4 tumors, vessel invasion, lymph node metastasis and distant metastasis were significantly more frequent than those in stage T1-T2 tumors. The mean MVD in tumors with positive IGF-II and HGF expressions was significantly higher than that in tumors without IGF-II and HGF expression. There were positive correlations between MVD and expression of IGF-II and HGF. The mean survival time and 5-year survival rate in cases with positive IGF-II and HGF expression and MVD value > or = 39.5 were significantly shorter those that in cases with negative IGF-II and HGF expression and MVD value < 39.5.


CONCLUSIONS
IGF-II and HGF promote angiogenesis in gastric cancer, and take part in tumor invasion and metastasis. They can be used as prognostic markers of gastric cancer in clinical practice.
Zhao
Zhong-sheng
ZS
Department of Pathology, Zhejiang Provincial Hospital, Hangzhou 310014, China. Tangyaping@sina.com
Ru
Guo-qing
GQ
Ma
Jie
J
D000231:Adenocarcinoma, Papillary / Q000098:blood supply / Q000378:metabolism / Q000556:secondary; D000328:Adult; D000368:Aged; D044584:Carcinoma, Ductal / Q000098:blood supply / Q000378:metabolism* / Q000556:secondary; D018279:Carcinoma, Signet Ring Cell / Q000098:blood supply / Q000378:metabolism / Q000556:secondary; D018450:Disease Progression; D005260:Female; D017228:Hepatocyte Growth Factor / Q000096:biosynthesis* / Q000235:genetics; D006801:Humans; D007335:Insulin-Like Growth Factor II / Q000096:biosynthesis* / Q000235:genetics; D008113:Liver Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008833:Microcirculation; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009389:Neovascularization, Pathologic; D010534:Peritoneal Neoplasms / Q000098:blood supply / Q000378:metabolism / Q000556:secondary; D011379:Prognosis; D012333:RNA, Messenger / Q000096:biosynthesis / Q000235:genetics; D013274:Stomach Neoplasms / Q000098:blood supply / Q000378:metabolism* / Q000473:pathology; D015996:Survival Rate
D012333:RNA, Messenger; D017228:Hepatocyte Growth Factor; D007335:Insulin-Like Growth Factor II